Publications by authors named "Rohini R Morey"
Article Synopsis
- Uveal melanoma (UM) is a serious cancer with limited treatment options, and this study investigates the effects of imipridones, which activate a protein called CLPP that can indirectly inhibit a harmful energy production process in the cancer cells.
- Researchers found that imipridones, specifically ONC201 and ONC212, reduce the growth and spread of UM cells in the lab and show promise in decreasing tumor size and increasing survival in animal models.
- The findings suggest that imipridones could be a new and effective treatment strategy for patients with metastatic uveal melanoma (mUM).
Purpose: Uveal melanoma (UM) is a highly aggressive disease with very few treatment options. We previously demonstrated that mUM is characterized by high oxidative phosphorylation (OXPHOS). Here we tested the anti-tumor, signaling and metabolic effects of imipridones, CLPP activators which reduce OXPHOS indirectly and have demonstrated safety in patients.
View Article and Find Full Text PDFPerivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors that express smooth muscle and melanocytic makers. Diagnosis of PEComas can be challenging due to focal or lost expression of traditional immunohistochemical markers, limited availability of molecular testing, and morphological overlap with much more common smooth muscle tumors. This study evaluates the use of glycoprotein nonmetastatic melanoma protein B (GPNMB) immunohistochemical staining as a surrogate marker for TSC1/2/MTOR alteration or TFE3 rearrangement to differentiate PEComas from other mesenchymal tumors.
View Article and Find Full Text PDF